Trovagene Company Profile (NASDAQ:TROV)

About Trovagene

Trovagene logoTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TROV
  • CUSIP:
Key Metrics:
  • Previous Close: $4.95
  • 50 Day Moving Average: $5.29
  • 200 Day Moving Average: $5.04
  • 52-Week Range: $2.85 - $7.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.42
  • P/E Growth: 0.00
  • Market Cap: $149.23M
  • Outstanding Shares: 30,147,000
  • Beta: 0.61
Additional Links:
Companies Related to Trovagene:

Analyst Ratings

Consensus Ratings for Trovagene (NASDAQ:TROV) (?)
Ratings Breakdown: 5 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $7.40 (50.71% upside)

Analysts' Ratings History for Trovagene (NASDAQ:TROV)
DateFirmActionRatingPrice TargetDetails
8/8/2016Cantor FitzgeraldUpgradeHold -> Buy$5.00 -> $7.00View Rating Details
8/5/2016Piper Jaffray Cos.Set Price TargetHold$5.00 -> $4.00View Rating Details
8/5/2016Maxim GroupBoost Price TargetBuy$9.00 -> $12.00View Rating Details
5/12/2016Leerink SwannReiterated RatingHoldView Rating Details
4/28/2016ArgusDowngradeBuy -> HoldView Rating Details
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00View Rating Details
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details
2/22/2016Jefferies GroupReiterated RatingBuyView Rating Details
(Data available from 9/1/2014 forward)


Earnings History for Trovagene (NASDAQ:TROV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.31)($0.34)ViewN/AView Earnings Details
5/10/2016Q116($0.29)($0.36)ViewListenView Earnings Details
3/10/2016Q415($0.25)($0.26)$100.00 millionViewListenView Earnings Details
8/10/2015Q215($0.24)($0.41)ViewListenView Earnings Details
5/5/2015($0.23)($0.24)ViewN/AView Earnings Details
3/12/2015Q414($0.26)($0.25)ViewN/AView Earnings Details
11/6/2014Q3 14($0.25)($0.28)ViewN/AView Earnings Details
8/11/2014($0.24)($0.18)ViewN/AView Earnings Details
5/12/2014($0.23)($0.17)ViewN/AView Earnings Details
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Trovagene (NASDAQ:TROV)
Current Year EPS Consensus Estimate: $-1.34 EPS
Next Year EPS Consensus Estimate: $-1.11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20162($0.33)($0.33)($0.33)
Q3 20162($0.38)($0.37)($0.38)
Q4 20161($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)


Dividend History for Trovagene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Trovagene (NASDAQ:TROV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Trovagene (NASDAQ:TROV)
DateHeadline logoLiquid Biopsy Market Driven by Increasing Adoption in Lung Cancer Indication (NASDAQ:TROV) - August 31 at 9:33 AM logoCancer Diagnostics Market Industry Analysis, Trend and Growth, 2015-2025 (NASDAQ:TROV) - August 30 at 11:12 AM logoTrovagene Inc (TROVU.OQ) (NASDAQ:TROV) - August 24 at 7:37 PM logoWill TrovaGene, Inc. (NASDAQ:TROV) Hit $9 Price Target? - Investor Newswire (NASDAQ:TROV) - August 23 at 12:25 PM
News IconCrowd & Street Monitoring TrovaGene, Inc. (NASDAQ:TROV) Shares - Post News (NASDAQ:TROV) - August 23 at 12:25 PM
News IconLiquid biopsy market worth 1.66 billion USD by 2021 according to new research report (NASDAQ:TROV) - August 19 at 10:49 AM logoTrovagene's (TROV) Liquid Biopsy Tests Will be Covered by BCBSIL (NASDAQ:TROV) - August 18 at 10:58 AM logoTROVAGENE, INC. : Other Events (form 8-K) (NASDAQ:TROV) - August 18 at 10:58 AM logoTROVAGENE, INC. Files SEC form 8-K, Other Events (NASDAQ:TROV) - August 17 at 8:12 PM
News IconStock Gapping Up Pre-Market: TrovaGene, Inc. (NASDAQ:TROV) - Post News (NASDAQ:TROV) - August 17 at 10:52 AM logo8:31 am TrovaGene signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Illinois (:BCBSIL) establishing health benefit access to the full line of Trovagene's tests and services (NASDAQ:TROV) - August 17 at 10:52 AM logoBlue Cross Blue Shield Illinois to Cover Trovera™ Liquid Biopsy Tests (NASDAQ:TROV) - August 17 at 10:52 AM logoETF’s with exposure to TrovaGene, Inc. : August 16, 2016 (NASDAQ:TROV) - August 16 at 7:59 PM logoTrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:TROV) - August 15 at 8:15 PM logoTROVAGENE, INC. Financials (NASDAQ:TROV) - August 12 at 8:01 PM logoLiquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product, End User - Forecast to 2021 (NASDAQ:TROV) - August 11 at 8:30 PM logoTrovera™ Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer (NASDAQ:TROV) - August 11 at 11:20 AM logoTrovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference (NASDAQ:TROV) - August 11 at 11:20 AM logo8 Biggest Price Target Changes For Monday - Benzinga (NASDAQ:TROV) - August 8 at 8:07 PM logoCantor Fitzgerald Upgrades Trovagene To Buy, Bullish On Clinical Business - Benzinga (NASDAQ:TROV) - August 8 at 8:07 PM
News IconStocks on the Move: VIVUS, Inc. (NASDAQ:VVUS), TrovaGene Inc(NASDAQ:TROV) - NYSE Journal (press release) (NASDAQ:TROV) - August 8 at 8:58 AM logoEdited Transcript of TROV earnings conference call or presentation 4-Aug-16 9:00pm GMT (NASDAQ:TROV) - August 6 at 7:51 PM logoTrovagene Reports Second Quarter 2016 Financial Results and Accomplishments (NASDAQ:TROV) - August 5 at 8:07 PM logoTrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise (NASDAQ:TROV) - August 5 at 10:57 AM logoTrovaGene Inc.: Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments - The Wall Street Transcript (NASDAQ:TROV) - August 4 at 8:23 PM logoTrovagene reports 2Q loss (NASDAQ:TROV) - August 4 at 8:23 PM logoQ2 2016 Trovagene Inc Earnings Release - 4:00 pm ET (NASDAQ:TROV) - August 4 at 11:08 AM logoProspera Financial Services Inc Lowers stake in TrovaGene Inc (TROV) - Trade Calls (NASDAQ:TROV) - August 3 at 11:12 AM logoWill TrovaGene (TROV) Pull an Earnings Surprise in Q2? (NASDAQ:TROV) - August 1 at 9:34 AM logoWill TrovaGene, Inc. (NASDAQ:TROV) Surprise Analysts? - Investor Newswire (NASDAQ:TROV) - July 26 at 8:24 PM logoTrovaGene Inc.: Trovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call - The Wall Street Transcript (NASDAQ:TROV) - July 26 at 8:24 PM logoTROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga (NASDAQ:TROV) - July 26 at 4:32 PM logoDiagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology (NASDAQ:TROV) - July 26 at 11:28 AM logoTrovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call (NASDAQ:TROV) - July 26 at 8:58 AM logoIs $12 Price Target Attainable For TrovaGene, Inc. (NASDAQ:TROV)? - Investor Newswire (NASDAQ:TROV) - July 24 at 7:20 PM
News IconTrovaGene, Inc. (NASDAQ:TROV): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:TROV) - July 22 at 10:49 AM
News IconIncreased Stock Volatility Watch: TrovaGene, Inc. (NASDAQ:TROV) - Engelwood Daily (NASDAQ:TROV) - July 20 at 8:56 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for TrovaGene, Inc. (NASDAQ:TROV) - TGP (NASDAQ:TROV) - July 20 at 10:46 AM
News IconEquity Roundup: Stock Performance Focus on TrovaGene, Inc. (NASDAQ:TROV) - Press Telegraph (NASDAQ:TROV) - July 20 at 10:46 AM logoTrovaGene Inc Stock Momentum at Critical Inflection Point - CML News (NASDAQ:TROV) - July 20 at 10:46 AM
News IconAre Analysts Bullish TrovaGene Inc (NASDAQ:TROV) After Last Week? - Consumer Eagle (NASDAQ:TROV) - July 18 at 9:13 AM logoStrong Sell Calls For TrovaGene, Inc. (NASDAQ:TROV) At 0 - Investor Newswire (NASDAQ:TROV) - July 18 at 9:13 AM
News IconTrovaGene, Inc. (NASDAQ:TROV) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:TROV) - July 16 at 11:04 AM
News IconShares Experiencing a Downtrend: TrovaGene, Inc. (NASDAQ:TROV) - TGP (NASDAQ:TROV) - July 16 at 11:04 AM logoTrovagene : and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer (NASDAQ:TROV) - July 15 at 1:13 PM
News IconAnalyst Target and Average Rating Watch: TrovaGene, Inc. (NASDAQ:TROV) - Press Telegraph (NASDAQ:TROV) - July 14 at 11:32 AM
News IconHC Stocks Growth: TrovaGene Inc (NASDAQ:TROV), Prima BioMed Ltd (ADR) (NASDAQ:PBMD) - share market updates (press release) (NASDAQ:TROV) - July 14 at 11:32 AM
News IconTrovaGene Inc Declines A lot Today, Is Now One of The Worst Performer - Consumer Eagle (NASDAQ:TROV) - July 14 at 11:32 AM
News IconTrovagene Inc (NASDAQ:TROV) Stock Price Loses While Sentiment Improves - Consumer Eagle (NASDAQ:TROV) - July 14 at 11:32 AM logoTrovaGene Inks Partnership with USC Norris Cancer Center (NASDAQ:TROV) - July 13 at 6:05 PM


Trovagene (NASDAQ:TROV) Chart for Thursday, September, 1, 2016

Last Updated on 9/1/2016 by Staff